The study reveals the HANR/miR-214/EZH2/TGF-β axis as a novel regulatory mechanism in HCC tumorigenesis and progression, providing insights for therapeutic strategies and diagnostic biomarkers targeting HANR. Here, EZH2 is linked to hepatocellular carcinoma.